This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Professionals 208 Users Online

Autogenous Vaccine For Aquaculture Market

Market Study of Autogenous Vaccine For Aquaculture: Enhancing Aquaculture Health with Custom-made Vaccines

Autogenous Vaccine for Aquaculture Market By Pathogen Type (Bacteria and Virus)

Autogenous Vaccine for Aquaculture Market Outlook (2023 to 2033)

Worldwide revenue from the Autogenous Vaccine For Aquaculture Market stands at US$ 12.6 Million in 2022, with the global market estimated to surge ahead at a CAGR value of 5.3% to reach a valuation of US$ 22.4 Million by the end of 2033.

Autogenous Vaccine for Aquaculture Market Size (2022)

US$ 12.6 Million

Projected Market Value (2033)

US$ 22.4 Million

Global Market Growth Rate (2023 to 2033)

5.3% CAGR

Market Share of Top 5 Countries

53.8%

As assessed by Persistence Market Research, the Salmon fish species are slated to hold around 42% share in the Autogenous vaccine for aquaculture market by 2033. Overall, Autogenous Vaccine for Aquaculture market sales accounts for approximately 9.7% of revenue share in the global veterinary vaccines market, which was valued at around US$ 10.4 Billion in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Autogenous Vaccine for Aquaculture from 2015 to 2022 Vs Market Outlook for 2023 to 2033

The global market for Autogenous Vaccines for Aquaculture recorded a historic CAGR of 4.7% in the last 7 years from 2015 to 2022.

Commercial autogenous aquaculture vaccines are licensed vaccines that enable an aquatic species to build a host immune response. Long-term aquaculture cultivation and increased aquaculture output have caused aquaculture farming to decline, which has increased the prevalence of viral diseases or zoonotic infections.

Due to increased rates of infection and newly emerging zoonotic infections causing significant financial fatalities, disease profiling across aquatic species has recently become more complicated. This trend is expected to boost the demand for aquaculture vaccines worldwide. The disease management paradigm in aquaculture production has had to change as a result of this scenario.

In other words, commercial fish aquaculture vaccines are being developed and marketed to reduce the adverse effects of antibiotic usage, prevent disease, produce safer food, and enhance external factors like the quality of the farming environment. For instance, recent research shows that Norway's increased use of commercial aquaculture vaccines in salmon aquaculture farming has helped to significantly reduce the consumption of antibiotics in aquaculture farms.

Additionally, The FAO and its partners launched the ground-breaking PMP/AB (Progressive Management Pathway for Improving Aquaculture Biosecurity) initiative in 2018. It was established as an expansion of the progressive control pathway (PCP) strategy, which has been widely used to assist countries to form systematic frameworks for developing and implementing risk reduction plans for the reduction, elimination, and eradication of important cattle and zoonotic diseases. Realistic disease control objectives can be established and achieved attributable to this methodical approach. The growing support by authorities towards zoonotic prevention and aquaculture biosecurity has positively impacted steady growth in the aquaculture related market.

The global autogenous vaccine for aquaculture market is thus likely to show high growth over the coming years a CAGR value of 5.3% and reach a global market size of US$ 22.4 Million by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can Manufacturers of Autogenous Vaccine for Aquaculture Grow?

Emergence of resistance to certain antibiotics surged the demand for Autogenous Vaccines

Over the past ten years, a plethora of new aquaculture vaccines have been introduced for the management of zoonotic infection or disease profiling among aquatic species, and more research and development are currently underway. In tropical and subtropical areas, there is a rising demand for aquaculture vaccines, according to the veterinary healthcare sector. The demand for vaccinations is rising as a result of the emergence of resistance to certain antibiotics and chemotherapeutic drugs.

Third-generation DNA vaccine development and commercialization against aquatic pathogens is a developing area of research and development in the autogenous vaccines for aquaculture market. DNA vaccines are thought to provide long-lasting immune protection and are incredibly effective.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

What is the Regulatory Impact on Global Sales of Autogenous Vaccines for the Aquaculture Market?

Protracted regulatory procedures may hinder the commercialization of a vaccines

Most countries have their regulatory agencies and processes for approving autogenous vaccines for aquaculture. Multiple applications for approval for each country are seen to be a major barrier to the speedy commercialization of autogenous vaccines for fisheries. Additionally, the cost of fragmented product distribution is so high that a services provider needs wait years to receive all regulatory approvals. In such cases, one company is prohibited from releasing new or improved products before receiving all permits. Prior to commencing to distribute their products, autogenous vaccines manufacturers need to wait for regulatory licences. Such terms are anticipated to slow the market's expansion for autogenous aquaculture vaccinations.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the United States Autogenous Vaccine for Aquaculture Market Growing?

“Supports towards sustainable seafood marks opportunities in the United States

The United States accounted for nearly 84.4% market share in the North American autogenous vaccine for aquaculture market in 2022, and a similar trend is expected over the forecast period. The United States was the primary export market in 2021, followed by Japan, Brazil, Russia, and Mexico, according to the Chilean Salmon Council. Over 85% of exports come from these five nations, with the United States expanding by 33.7% and Brazil by 63.5% from the previous year.

Based on value, bivalve mollusks including oysters, clams, and mussels make up more than 80% of marine aquaculture production in the United States The majority of the remaining fish are salmon and shrimp, but new technologies, aquaculture feeds, and management strategies are allowing other species to be made available to American consumers widely.

According to the most recent edition of "Fisheries of the United States," marine aquaculture accounts for 7% of all domestic seafood production in terms of weight. However, because of the emphasis on high-value items, aquaculture now accounts for 24% of the value of domestic seafood. There is a strong rationale for increasing domestic aquaculture production. The United States is the world's top importer of fish and fishery products and a major supplier of technology, feed, machinery, and capital to other producers across the globe. These characteristics assist the United States in building a sustainable aquaculture sector to satisfy the nation's expanding demand for fresh seafood.

How big is the Opportunity in Norway's Autogenous Vaccines for Aquaculture Market?

Norway held the largest market share of 33.3% within the European region. Throughout the forecast period, PMR expects Europe to continue to be one of the most promising opportunities for autogenous aquaculture vaccinations. The demand for fish meals made without antibiotics and the rising aquaculture production in the area are two major factors promoting development. Norway fish aquaculture farming is evolving into one of the most dependable and high-quality providers of fish food free of antibiotics to developed nations in the North American and European areas. Along with government assistance, fish farming businesses in Norway are expanding quickly and switching to commercial aquaculture vaccines instead of antibiotics. Additionally, Norway continues to be one of the world's largest markets for commercial aquaculture vaccinations, making it a lucrative niche for manufacturers of commercial aquaculture vaccines.

The adoption of commercial aquaculture vaccines in Norway has been made possible by favourable insurance policies, high per capita spending, the presence of top manufacturers, and the greatest aquaculture production in the rising European countries.

How is Chile Emerging as a Prominent Market for Autogenous Vaccines for the Aquaculture industry?

“Chile ranks second in salmon production and exports”

Chile held the second largest market share of about 28.1% of the Latin America autogenous vaccines for aquaculture market in 2022.

Chile which ranks second in both salmon production and exports is open to American advances that support sustainability. Chile develops sustainable aquaculture attributable to its comparative and competitive advantages. The animal protein that lends itself to aquaculture the best is salmon, which may be used for human food as well as other purposes. The carbon footprint of salmon aquaculture is ten times smaller than that of stockbreeding and requires 13 times less water. Salmon farming in Chile, began 40 years ago and has become one of the country’s economic success tales, with $5.2 billion in exports projected for 2021. The sector has also supported over 4,000 businesses and produced over 70,000 jobs in Chile's three most southern regions, Los Lagos, Aysén, and Magallanes.

The largest salmon farmers' trade group, the Chilean Salmon Council, and the Monterey Bay Aquarium have joined forces to further minimize antibiotic usage by 50% by 2025. Leading salmon farming businesses in Chile and suppliers to the sector signed a Clean Production Agreement in 2021 to control water and carbon use and lower energy consumption. Additionally, production facilities have started implementing new technologies including underwater robotics, online environmental monitoring, and high-end.

Category-wise Insights

Which Type of Fish Species Gained Popularity and Anticipates the Growth of the Global Autogenous Vaccines for the Aquaculture Market?

“Salmon holds the highest share in the global market”

During the forecast period, salmon species would hold more than 40% of the market share for autogenous aquaculture vaccines due to the rising demand for salmon as fish food in developed countries. In addition, salmon species are preferred for aquaculture cultivation in important vaccine nations like Chile and Norway.

For instance, studies from the Institute of Food and Agriculture Sciences (IFAS) indicate that the use of autogenous vaccines for aquaculture, notably in the salmon business, has been a major factor in the success of salmon aquaculture rearing and production for about 30 years.

According to Food and Agriculture Organization (FAO), 2022 data, a 0.2 per cent increase over 2019 and a 0.6 per cent decrease over the previous record production of 2018 are represented by the production of aquatic animals. Due to the COVID-19 pandemic's effects and other variables, capture fisheries decreased by 4.4 per cent in 2019 compared to 2018 and by a further 2 per cent in 2020. However, capture fisheries are still generally stable, and the overall production in 2020 is very similar to the average yearly production from 1995 to 2020. Aquaculture showed an increase over the last two years despite the reduction in capture fisheries, but at a slower annual rate. The outcome was that in 2020, 157 million tonnes of aquatic creatures were produced specifically for human consumption, which was the second-highest on record.

Which Pathogen Type Drives Demand the Most for Autogenous Vaccines for Aquaculture Market?

“Bacterial conjugated vaccines are on demand.”

Bacteria held the largest market share of around 92.1% in 2022 and is expected to dominate the market throughout the forecast period with a high growth rate of 5.4%.

The USDA's Aquatic Animal Health Research has determined that bacterial species from more than 20 genera are the primary causes of aquatic illnesses. They have an impact on more than 20 species of freshwater and marine fish. Aquatic diseases are thought to be responsible for hundreds of millions of dollars in annual economic losses in the aquaculture sector.

A novel vaccine known as DNA vaccination has recently been constructed using the DNA of an infectious pathogen. It functions by introducing viral or bacterial DNA (and expressing it, causing the immune system to recognize it) into animal cells. The primary bacterial virulence mechanism would be neutralized by focusing on the known bacterial proteins that are involved in complement inhibition.

Which End User Segment Drives the Demand for Global Market?

Fish farming companies held the largest market share of about 81.5% within the global market and is expected to continue dominating this sector over the forecast period. The booming aquaculture farming has witness the explored lucrative opportunities for fish farming companies witnessing its dominance in the global market

Competitive Landscape

Companies in the autogenous vaccines for aquaculture market are focusing on strategic acquisitions of new, and innovative ideas, and partnerships that improve the value chain. The leading manufacturers of commercial aquaculture vaccines are concentrating extensively on the subject that aquaculture farmers are facing and addressing their needs for sustainable fish aquaculture farming through the introduction of efficient and practical commercial aquaculture vaccine development and production. This strategy is anticipated to increase their sales footprint in the global autogenous vaccines for the aquaculture market.

For instance:

  • In April 2021, ICAR launched CIBA-Nodavac-R to tackle VNN, which affects many marines, freshwater fish, and brackishwater that can result in up to 100% mortality in the larval and early juvenile stages. The virus that causes nerve necrosis is the disease (NNV). An injectable recombinant VNN vaccine called CIBA-Nodavac-R can successfully prevent vertical transmission in brooders and VNN induced by RGNNV in fingerlings.
  • In January 2021, with its ground-breaking microalgae-based oral delivery technology, TransAlgae seeks to influence the future of vaccination in the aquaculture industry. Virbac and TransAlgae have signed an exclusive business development collaboration agreement. The businesses have a long-term business relationship and have inked an exclusive collaboration agreement to create a vaccine using TransAlgae's innovative technology.

Similarly, recent developments related to companies manufacturing autogenous vaccines for aquaculture have been tracked by the team at Persistence Market Research, which is available in the full report.

Autogenous Vaccines for Aquaculture Industry Report Scope

Attribute

Details

Forecast Period

2023 to 2033

Historical Data Available for

2015 to 2022

Market Analysis

USD Million for Value

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Mexico
  • Peru
  • Chile
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Norway
  • Greece
  • Russia
  • China
  • Singapore
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • South Africa

Key Market Segments Covered

  • Fish species
  • Pathogen Type
  • End-User
  • Region

Key Companies Profiled

  • IDT Biologika GmbH (Ridgeway Biologicals Ltd)
  • MARINNOVAC (AQUATRECK ANIMAL HEALTH S.L.)
  • Ceva Biovac
  • Zoetis
  • Vaxxinova
  • Barramundi Asia Pte Ltd.(UVAXX Asia)
  • HIPRA
  • AniCon Labor GmbH
  • sanphar (ipeve)
  • Kennebec River Biosciences

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Autogenous Vaccines for Aquaculture Industry Research

By Fish Species:

  • Salmon
  • Tilapia
  • Bream
  • Labris Bergylta
  • Cyprinus Carpio
  • Sea Bass
  • Cyclopterus Lumpus
  • Trout

By Pathogen Type:

  • Bacteria
  • Virus

By End User:

  • Fish Farming Companies
  • Aquatic Research Institute

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • IDT Biologika GmbH (Ridgeway Biologicals Ltd)
  • MARINNOVAC (AQUATRECK ANIMAL HEALTH S.L.)
  • Ceva Biovac
  • Zoetis (PHARMAQAS)
  • Vaxxinova
  • Barramundi Asia Pte Ltd.(UVAXX Asia)
  • HIPRA
  • AniCon Labor GmbH
  • sanphar (ipeve)
  • Kennebec River Biosciences

- Frequently Asked Questions -

The global autogenous vaccines for the aquaculture market are currently valued at around US$ 12.6 Mn in 2022.

Sales of autogenous vaccines for the aquaculture market are set to witness a high growth rate of 5.3% and be valued at US$ 22.4 Mn by 2033.

Demand for autogenous vaccines for the aquaculture market increased at 4.7% CAGR from 2015 to 2022.

The U.S., Norway, Spain, Brazil, and Chile account for the most demand for autogenous vaccines for aquaculture currently holding 53.8% market share.

The U.S. accounts for around 84.4% share of the North American market.

Zoetis, HIPRA, and Vaxxinova are the top three manufacturers of autogenous vaccines for aquaculture.

China market held a share of about 1.4% in the global autogenous vaccines for the aquaculture market in 2022.

Germany is expected to grow at a moderate growth rate of 4.0% over the forecast duration.

Google translate